Guided Therapeutics Announces $550,000 Increase to $4 Million Private Placement and Accelerated Interim Closing

NORCROSS, Ga.–(BUSINESS WIRE)–Guided Therapeutics, Inc. (OTCQB: GTHP) announced today that it has
entered into an amendment agreement to increase by $550,000 the gross
cash proceeds from its previously announced private placement of
convertible preferred stock and common stock warrants, as well as to
accelerate the closing of $1.3 million of the total $4.55 million
investment. Among those making the additional investment is a member of
the Company’s Board of Directors.

Net proceeds from the private placement are intended to be used to
purchase new inventory for manufacturing the Guided Therapeutics LuViva®
Advanced Cervical Scan.

Gene Cartwright, CEO of Guided Therapeutics, stated, “These additional
funds are needed to cover the cost of manufacturing additional LuVivas
and single-use disposables for the previously announced Ministry of
Health order for Turkey.”

Pursuant to the amendment agreement, dated September 3, 2015, at an
interim closing expected to occur as early as today, the Company will
issue to participating investors 1,734 shares of preferred stock and
five-year warrants to purchase approximately 27.3 million shares of
common stock, at an exercise price of $0.095 per share, all on the same
terms as previously announced.

The final closing of the private placement is scheduled to occur in the
fourth quarter of 2015, at which the Company would receive the final
$750,000 in gross cash proceeds. Total gross cash proceeds from the
private placement are expected to be $4.55 million, an increase of
$550,000 from the amount originally announced.

Neither the preferred stock, nor the warrants to purchase shares of
common stock, nor the shares of common stock issuable upon conversion of
the preferred stock or exercise of warrants, have been registered under
the Securities Act of 1933, as amended, and none of these securities may
be offered or sold in the United States absent registration or an
applicable exemption from registration requirements. This news release
shall not constitute an offer to sell or the solicitation of an offer to
buy these securities, nor shall there be any sale of these securities in
any jurisdiction where such offer, solicitation or jurisdiction would be
unlawful.

About LuViva® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the
cervix with light and uses spectroscopy to measure how light interacts
with the cervical tissue. Spectroscopy identifies chemical and
structural indicators of precancer that may be below the surface of the
cervix or misdiagnosed as benign. This technique is called biophotonics.
Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory
analysis or a tissue sample, and is designed to provide results
immediately, which may result in eliminating costly, painful and
unnecessary additional testing. LuViva is intended for use with women
who have undergone initial screening and are called back for follow up
with a colposcopy examination, which in many cases, involves taking a
biopsy of the cervix. It has also been used in clinical studies in
Turkey and Nigeria as a means to screen women for cervical cancer where
the availability of infrastructure necessary for Pap and HPV testing is
restricted. The device is used in conjunction with the LuViva®
Cervical Guide single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and
painless testing platform based on its patented biophotonic technology
that utilizes light for the early detection of disease at the cellular
level. The Company’s first product is the LuViva® Advanced
Cervical Scan, a non-invasive device used to detect cervical disease
instantly and at the point of care. In a multi-center clinical trial,
with women at risk for cervical disease, the technology was able to
detect cervical cancer up to two years earlier than conventional
modalities, according to published reports. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva® Advanced Cervical Scan is an
investigational device and is limited by federal law to investigational
use in the U.S. LuViva, the wave logo and “Early detection, better
outcomes” are registered trademarks owned by Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and
subject areas discussed in this news release that are not historical or
current facts deal with potential future circumstances and developments,
including among others, the timing of the closing of the private
placement and the amount of gross proceeds and the use of net proceeds
from the private placement. The discussion of such matters and subject
areas is qualified by the inherent risks and uncertainties surrounding
future expectations generally and also may materially differ from Guided
Therapeutics’ actual future experience involving any of or more of such
matters and subject areas. Such risks and uncertainties include those
related to the Company’ ability to complete the transactions
contemplated by the private placement, its ability to realize the
expected benefits of the private placement, the sufficiency of the
capital raised in the private placement and the ability of Guided
Therapeutics to raise additional capital, the extent of dilution of the
holdings of its current stockholders upon conversion or exercise of
securities issued in connection with capital raising efforts, the early
stage of Guided Therapeutics products in development, the uncertainty of
market acceptance of products, the uncertainty of development or
effectiveness of distribution channels, the intense competition in the
medical device industry, the uncertainty of capital to develop products
or continue as a going concern, the uncertainty of regulatory approval
of products, dependence on licensed intellectual property, as well as
those that are more fully described from time to time under the heading
“Risk Factors” in Guided Therapeutics’ reports filed with the Securities
and Exchange Commission, including Guided Therapeutics’ Annual Report on
Form 10-K for the fiscal year ended December 31, 2014, and subsequent
quarterly reports.

Contacts

Investor and Media Relations Contact:
IRTH Communications
Robert
Haag, 866-976-4784
Managing Partner
GTHP@irthcommunications.com
or
Guided
Therapeutics
Bill Wells, 770-242-8723